Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant

Area of Science:

• Virology
• Vaccinology
• Biotechnology

Background:

• Coronaviruses periodically cause fatal human infections, necessitating rapid vaccine development.
• Existing vaccine platforms may not meet the urgent need for scalable coronavirus countermeasures.

Purpose of the Study:

• To describe an insect cell expression system for the rapid production of a severe acute respiratory syndrome coronavirus (SARS) vaccine.
• To present detailed methods for antigen production, purification, and testing.
• To highlight the system's applicability for developing vaccines against other fatal human coronaviruses.

Main Methods:

• Utilizing an insect cell expression system for recombinant protein production.
• Purification and rigorous release testing of the SARS spike protein antigen.
• Adjuvant formulation and subsequent animal model testing.

Main Results:

• Successful expression, purification, and testing of SARS recombinant spike protein antigen.
• Demonstration of a highly protective SARS vaccine through animal studies.
• Validation of the insect cell system for rapid vaccine development.

Conclusions:

• The insect cell expression system provides a viable platform for the rapid production of effective coronavirus vaccines.
• This methodology can be readily adapted for the swift development of vaccines against emerging and re-emerging coronaviruses, including MERS-CoV.
• Accelerated vaccine development is critical for mitigating the impact of future coronavirus pandemics.